Circulating levels of insulin-like growth factor I, its binding proteins-1,-2, -3, C-peptide and risk of postmenopausal breast cancer
Circulating levels of insulin-like growth factor I, its binding proteins-1,-2, -3, C-peptide and risk of postmenopausal breast cancer
复制标题
DOI：
10.1002/ijc.11193
复制
发表时间：
2003-08-10
影响因子：
6.4
通讯作者：
Peeters, PHM
中科院分区：
文献类型：
--
作者：
Keinan-Boker, L;de Mesquita, HBB;Peeters, PHM
较高水平的循环胰岛素样生长因子（IGF）-I可能与绝经前乳腺癌的高风险有关。我们研究了循环中IGF-I及其结合蛋白（IGFBPs）-1、-2、-3、C肽水平与绝经后乳腺癌之间的关系。这是一项嵌套在2个荷兰队列中的前瞻性研究。研究人群包括基线时绝经后的女性。乳腺癌病例是通过与癌症登记处的联系确定的。对照组按队列、年龄、献血日期和居住地与病例相匹配。共纳入149例乳腺癌病例和333例健康对照。通过放射免疫测定法测定血浆IGF-I、IGFBP-I、IGFBP-2、IGFBP-3和C肽水平。通过条件logistic回归获得与肽循环水平的四分位数相关的乳腺癌相对风险的估计值。模型根据BMI、初潮年龄和首次足月分娩年龄进行调整。对于IGF-I，上四分位数与下四分位数的校正OR（95% CI）为1.1（0.6; 2.1）; IGFBP-I为0.7（0.3; 1.3）;对于IGFBP-2，1.1（0.5; 2.4）;对于IGFBP-3，1.6（0.7; 3.5）;对于C-肽，1.3（0.7; 2.7）和对于IGF-I/IGFBP-3比率，1.0（0.5; 1.8）。我们的数据不支持绝经后循环中IGF-I、IGFBP-I、-2、-3、C肽水平与绝经后乳腺癌之间存在关联。(C)2003 Wiley-Liss，Inc.
Higher levels of circulating Insulin-like Growth Factor (IGF)-I may be associated with higher risks for premenopausal breast cancer. We investigate the associations between circulating levels of IGF-I, its binding proteins (IGFBPs) -1, -2, -3, C-peptide and postmenopausal breast cancer. This is a prospective study nested in 2 Dutch cohorts. The study population included women who were postmenopausal at baseline. Breast cancer cases were identified through linkage with cancer registries. Controls were matched to cases by cohort, age, date of blood donation and place of residence. In total, 149 breast cancer cases and 333 healthy controls were included. Plasma levels of IGF-I, IGFBP-I, -2, -3 and C-peptide were measured by radioimmunoassays. Estimates of the relative risk for breast cancer associated with the quartiles of the peptides' circulating levels were obtained by conditional logistic regression. Models were adjusted for BMI, age at menarche and age at first full-term delivery. For IGF-I, the adjusted OR (95% CI) of the top vs. bottom quartile was 1.1 (0.6; 2.1); for IGFBP-I it was 0.7 (0.3; 1.3); for IGFBP-2, 1.1 (0.5; 2.4); for IGFBP-3, 1.6 (0.7; 3.5), for C-peptide, 1.3 (0.7; 2.7) and for IGF-I/IGFBP-3 ratio, 1.0 (0.5; 1.8). Our data do not support an association between postmenopausal circulating levels of IGF-I, IGFBP-I, -2, -3, C-peptide and postmenopausal breast cancer. (C) 2003 Wiley-Liss, Inc.